Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial

Core Insights - Amplia Therapeutics Limited announced mature data from the ACCENT clinical trial for advanced pancreatic cancer, showing a median overall survival of 11.1 months and five complete responses recorded to date [2][9]. Clinical Trial Data - The ACCENT trial has reported a confirmed complete response (CR) rate of 7.8% (5 out of 64 patients) for those receiving a 400 mg dose of narmafotinib, which is unprecedented for this indication [3][9]. - An updated Objective Response Rate (ORR) of 35.9% (23 out of 64 patients) has been established, with one patient nearing 24 months on the trial [4][9]. - The median overall survival (mOS) of 11.1 months represents a two-month improvement compared to the standard gemcitabine-Abraxane chemotherapy [6][9]. Comparative Analysis - The ACCENT trial data compares favorably to historical data from the MPACT and NAPOLI 3 trials, with the mOS of 11.1 months being identical to that of the NALIRIFOX regimen, which received FDA approval [7][8]. - The complete response rate of 7.8% in the ACCENT trial significantly exceeds the rates of 0.2% and 0.3% reported in the MPACT and NAPOLI 3 trials, respectively [8]. Safety and Tolerability - Narmafotinib has been well tolerated by patients, with the adverse effect profile similar to that of chemotherapy alone [8][9]. Upcoming Presentations - The company has been selected to present trial data at the American Association of Cancer Research (AACR) annual meeting in April 2026 [10][11].